279 related articles for article (PubMed ID: 36871057)
21. Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment "jigsaw puzzle".
Dzobo K
OMICS; 2019 Feb; 23(2):70-85. PubMed ID: 30767728
[TBL] [Abstract][Full Text] [Related]
22. BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.
Genta S; Pirosa MC; Stathis A
Curr Oncol Rep; 2019 Feb; 21(2):13. PubMed ID: 30715616
[TBL] [Abstract][Full Text] [Related]
23. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
[TBL] [Abstract][Full Text] [Related]
24. A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
Chung C
Blood Lymphat Cancer; 2022; 12():99-106. PubMed ID: 35959380
[TBL] [Abstract][Full Text] [Related]
25. The many layers of epigenetic dysfunction in B-cell lymphomas.
Jiang Y; Dominguez PM; Melnick AM
Curr Opin Hematol; 2016 Jul; 23(4):377-84. PubMed ID: 27055146
[TBL] [Abstract][Full Text] [Related]
26. Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.
Makita S; Hosoba R; Tobinai K
Expert Opin Drug Saf; 2020 Sep; 19(9):1105-1120. PubMed ID: 32715803
[TBL] [Abstract][Full Text] [Related]
27. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
Ramadoss M; Mahadevan V
Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
[TBL] [Abstract][Full Text] [Related]
28. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
Zain J; O'Connor OA
Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
[TBL] [Abstract][Full Text] [Related]
29. Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise.
Morel D; Jeffery D; Aspeslagh S; Almouzni G; Postel-Vinay S
Nat Rev Clin Oncol; 2020 Feb; 17(2):91-107. PubMed ID: 31570827
[TBL] [Abstract][Full Text] [Related]
30. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
31. Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma.
Ribeiro ML; Reyes-Garau D; Armengol M; Fernández-Serrano M; Roué G
Front Genet; 2019; 10():986. PubMed ID: 31681423
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic targets in B- and T-cell lymphomas: latest developments.
Ribeiro ML; Sánchez Vinces S; Mondragon L; Roué G
Ther Adv Hematol; 2023; 14():20406207231173485. PubMed ID: 37273421
[TBL] [Abstract][Full Text] [Related]
33. Genomic and epigenomic profile of thyroid cancer.
Acuña-Ruiz A; Carrasco-López C; Santisteban P
Best Pract Res Clin Endocrinol Metab; 2023 Jan; 37(1):101656. PubMed ID: 35461756
[TBL] [Abstract][Full Text] [Related]
34. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
35. Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.
Longley J; Johnson PWM
Curr Oncol Rep; 2021 May; 23(7):76. PubMed ID: 33937922
[TBL] [Abstract][Full Text] [Related]
36. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.
Otsuka Y; Nishikori M; Arima H; Izumi K; Kitawaki T; Hishizawa M; Takaori-Kondo A
Mol Immunol; 2020 Mar; 119():35-45. PubMed ID: 31962268
[TBL] [Abstract][Full Text] [Related]
37. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
38. Growth inhibition and transcriptional effects of ribavirin in lymphoma.
Dominguez-Gomez G; Cortez-Pedroza D; Chavez-Blanco A; Taja-Chayeb L; Hidalgo-Miranda A; Cedro-Tanda A; Beltran-Anaya F; Diaz-Chavez J; Schcolnik-Cabrera A; Gonzalez-Fierro A; Dueñas-Gonzalez A
Oncol Rep; 2019 Sep; 42(3):1248-1256. PubMed ID: 31322273
[TBL] [Abstract][Full Text] [Related]
39. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
40. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
Lue JK; Amengual JE
Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
